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Abstract
An important objective in biomedical risk assessment is estimation of minimum exposure levels that
induce a pre-specified adverse response in a target population. The exposure/dose points in such
settings are known as Benchmark Doses (BMDs). Recently, parametric Bayesian estimation for
finding BMDs has become popular. A large variety of candidate dose-response models is available
for applying these methods, however, leading to questions of model adequacy and uncertainty. Here
we enhance the Bayesian estimation technique for BMD analysis by applying Bayesian model aver-
aging to produce point estimates and (lower) credible bounds. We include reparameterizations of
traditional dose-response models that allow for more-focused use of elicited prior information when
building the Bayesian hierarchy. Performance of the method is evaluated via a short simulation
study. An example from carcinogenicity testing illustrates the calculations.
Keywords: Bayesian BMDL, Bayesian model averaging, benchmark analysis, dose-response anal-
ysis, hierarchical modeling, model uncertainty, multimodel inference, prior elicitation, quantitative
risk assessment.
1 Introduction
1.1 Benchmark Risk Analysis
An important objective in quantitative risk assessment is characterization of detrimental
or adverse responses after exposure to biological, chemical, physical, environmental, or other
hazardous agents (Stern, 2008). In this context, the risk is often quantified via a dose-
response function, R(d) (also called the risk function), which is defined as the probability of
exhibiting the adverse effect in a subject, object, or system exposed to a particular dose or
exposure level, d, of the agent. For biomedical and environmental risk applications, statistical
dose-response models are fit to data from bioassays on small mammals or other biological
systems, or from epidemiological analyses of human populations at risk. The observations
in such risk assessments are often in the form of proportions. This is the quantal response
setting, and is our focus here.
A modern approach to quantal-response risk estimation is known as benchmark analysis.
First introduced for toxicological applications by Crump (1984), this method uses a specific
functional assumption on R(d) to provide low-dose estimates for the risk. When applied
in biomedical or other public health settings, however, adjustments for spontaneous effects
must be introduced, re-expressing the risk in terms of an excess-above-background, exposure-
related rate (Piegorsch and Bailer, 2005, §4.2.1). For instance, with quantal data the extra
risk function RE(d) =
R(d)−R(0)
1−R(0)
, where R(0) is the background risk, is frequently employed.
From this, the benchmark dose (BMD) is calculated by inverting RE(d) at a predetermined
level of risk; the latter is called the benchmark risk or benchmark response (BMR). In effect,
we solve for d = BMD in RE(BMD) = BMR ∈ (0, 1); BMRs between 0.01 and 0.10 are most
often seen in practice (U.S. EPA, 2012). If the exposure is measured as a concentration, the
benchmark point is referred to as a benchmark concentration (BMC), if exposure is some sort
of quantitative index the benchmark point is a benchmark index (BMI), etc. To illustrate,
consider the following example.
Example 1. Benchmarking mammalian carcinogenicity of cumene.
Cumene, the colloquial name for isopropylbenzene (C9H12), is a hydrocarbon solvent em-
ployed in the production of industrial compounds such as phenol and acetone. Occupational
and industrial exposures to cumene are common, so the U.S. National Toxicology Program
(NTP) explored various forms of mammalian toxicity to the chemical (U.S. NTP, 2009).
For example, Table 1 displays quantal-response data on induction of lung tumors (alveo-
lar/bronchiolar adenomas and carcinomas) by cumene in laboratory mice after two year
chronic inhalation exposure.
Table 1: Quantal carcinogenicity data: Alveolar/bronchiolar adenomas and carcinomas in female
B6C3F1 mice after inhalation exposure to cumene (C9H12). Source: U.S. NTP (2009).
Exposure conc. (ppm), di 0 125 250 500
Animals with tumors, Yi 4 31 42 46
Animals tested, Ni 50 50 50 50
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In the table, a clear dose response is evidenced. Of additional interest, however, is
calculation of a benchmark exposure level to inform risk characterization of this potential
carcinogen. Notice that the C9H12 exposure dose, d, is actually a concentration (in ppm)
here, and so technically we will compute benchmark concentrations (BMCs) based on the
quantal carcinogenicity data. A benchmark analysis of these data appears Section 4.
One critical enhancement in benchmark analysis is construction of statistical confidence
(or credible) intervals for the BMD to account for variability in the estimation process.
Driven by public health or other safety considerations, only one-sided, lower limits are em-
ployed, denoted as BMDLs (Crump, 1995). Where needed for clarity, we add a subscript
for the BMR level at which each quantity is calculated: BMD100BMR and BMDL100BMR. In
this fashion, BMDs and BMDLs are employed for risk characterization by a number of
government and private entities. Their use for quantifying and managing risk with a vari-
ety of biological endpoints is growing in both the United States and the European Union
(U.S. General Accounting Office, 2001; European Union, 2003; OECD, 2006, 2008).
1.2 Parametric Bayesian Benchmark Analysis
Statistical estimation of the BMD is fairly well-developed under a frequentist schema
(Piegorsch and Bailer, 2005, §4.3); however, Bayesian benchmark analysis has only recently
garnered appreciative attention. Some modern advances can be found in Naufal et al. (2009);
Shao and Small (2011); Shao (2012); Wheeler and Bailer (2012); and Guha et al. (2013).
Notably, these sources for calculating Bayesian BMDs generally parameterize the model
in terms of standard regression-type quantities. For example, the logistic dose response
R(d) = (1+exp{−β0−β1d})−1 is popular, with β0 and β1 representing the intercept and slope,
respectively, of the risk on a logit scale. Under this sort of traditional parameterization, the
Bayesian hierarchy is usually presented with objective and/or improper prior distributions for
the unknown β-parameters. [Some noteworthy exceptions include incorporation at the prior
level of historical control information related to β0; see Shao (2012) and Wheeler and Bailer
(2012).] Indeed, it is unusual for truly informative, risk-analytic, prior knowledge to be
available on regression-type parameters such as β0 and β1, since their interpretation is so
generic. Unfortunately, this strategy can neglect informative prior information available on
the true quantity of interest in this setting, the BMD.
Of course, prior information on the BMD may not always exist in practice, and in this
case objective priors serve a useful purpose. When informative prior knowledge is avail-
able, however, the Bayesian paradigm can achieve its full potential. Along these lines, we
previously developed reparameterized dose-response models that explicitly incorporate the
BMD and other pertinent parameters into the model hierarchy (Fang and Piegorsch, 2014).
When applied to Bayesian dose-response modeling, these reparameterizations allow for more
practical elicitation of prior information in a benchmark analysis. Our method assumes,
however, that the choice of dose-response function is made without any uncertainty, i.e.,
that the specification for R(d)—reparameterized or otherwise— is unambiguous and correct.
In practice, the extensive library of quantal dose-response forms for R(d) available to the risk
assessor can lead to uncertainty in the model specification. To mitigate concerns over model
adequacy/uncertainty, recent works employ model averaging techniques. Bayesian model
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averaging (BMA; see Hoeting et al., 1999) has become popular in this regard, and a number
of articles have applied some form of BMA to benchmark analysis; see, e.g., Bailer et al.
(2005); Morales et al. (2006); Shao and Small (2011); Shao (2012); Shao and Gift (2014);
and the references therein. Most of these employ traditional β-parameterizations with ob-
jective priors, however. Here, we study the BMA approach for benchmark analysis by
using the reparameterized framework from Fang and Piegorsch (2014). Section 2 reviews
this reparameterized paradigm for hierarchical Bayesian benchmark analysis. Section 3 fol-
lows by connecting it with the elements of Bayesian model averaging. Section 4 returns to
the cumene carcinogenicity data from Table 1 to explore practical implementation of this
Bayesian model-averaged benchmark analysis, while Section 5 examines the characteristics
of our BMA Bayesian BMDLs via a short simulation study. Section 6 ends with a brief
discussion.
2 Hierarchical Bayesian Benchmark Analysis
2.1 Bayesian Dose-response Models
Under the quantal-response formulation, denote Yi as the number of responses, Ni as
the number of subjects tested, and R(di) as the unknown probability that an individual
subject will respond at (ordered) dose di ≥ 0, i = 1, . . . , m. Assume that, independently,
Yi ∼ Bin(Ni, R(di)). Let R(di) depend upon θ, an unknown parameter vector. The joint
p.m.f. of Y = (Y1, . . . , Ym) is then:
f(Y |θ) =
m∏
i
(
Ni
Yi
)
R(di)
Yi(1−R(di))Ni−Yi . (2.1)
Previous parametric representations for modeling R(d) in risk-analytic carcinogenic-
ity testing have focused on a suite of eight different functions (Wheeler and Bailer, 2009;
Piegorsch et al., 2013). These correspond to popular choices in the U.S. EPA’s BMDS soft-
ware (Davis et al., 2012), and are illustrated in Table 2. [Throughout, Φ(·) represents the
c.d.f. from the standard normal distribution.] Notice in the table that models M1–M4 em-
ploy only two unknown parameters, while models M5–M8 employ three. The BMD for each
model is obtained by first setting the extra risk function (as defined in Section 1) equal to
the BMR and then solving for d.
In applications of Bayesian benchmark analysis to quantal data, objective forms for the
prior p.d.f. pi(θ) are common, as indicated earlier. These typically appear as diffuse Gaussian
priors on the β-parameters. From this, the joint posterior distribution for θ is obtained from
Bayes formula (Casella and Berger, 2002, §7.2.3). An advantage here is that objective priors
are usually easy to apply: although they generally lead to intractable integrals, computer-
intensive operations such as Markov chain Monte Carlo (McMC) methods can produce a
corresponding sample from the joint posterior of θ (Robert and Casella, 2011). If the sample
is sufficiently large and stable, the output can be used to approximate the posterior, from
which inferences on the BMD may be conducted.
As we suggest above, a disadvantage with the traditional parameterizations in Table 2 is
that the β-parameters may have unclear subject-matter interpretations if those parameters
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Table 2: Common quantal-response models in toxicological and carcinogenic risk assessment. Note:
BMR∈ (0, 1) is the benchmark response and BMD is the benchmark dose
Code Name Risk Function, R(d) BMD Constraints
M1 Logistic (1 + exp{−β0 − β1d})−1 1β1 ln
(
1+BMRe−β0
1−BMR
)
—
M2 Probit Φ(β0 + β1d)
Φ−1{[1−Φ(β0)]BMR+Φ(β0)}−β0
β1
—
M3 Quantal-Linear 1− exp{−β0 − β1d} − 1β1 ln(1− BMR) β0 ≥ 0, β1 ≥ 0
M4 Quantal-Quadratic γ0 + (1−γ0)(1− e−β1d2)
√
− 1
β1
ln(1− BMR) 0 ≤ γ0 < 1, β1 ≥ 0
M5 Two-Stage 1− exp{−β0 − β1d− β2d2} −β1+
√
β2
1
−4β2 ln(1−BMR)
2β2
β0, β1, β2 ≥ 0
M6 Log-Logistic γ0 +
1−γ0
1+exp(−β0−β1 ln{d})
exp
{
ln( BMR
1−BMR
)−β0
β1
}
0 ≤ γ0 < 1, β1 ≥ 0
M7 Log-Probit γ0 + (1−γ0)Φ(β0 + β1 ln{d}) exp
{
Φ−1(BMR)−β0
β1
}
0 ≤ γ0 < 1, β1 ≥ 0
M8 Weibull γ0 + (1−γ0)(1− exp{−eβ0dβ1}) exp
{
ln(− ln[1−BMR])−β0
β1
}
0 ≤ γ0 < 1, β1 ≥ 1
are not the target quantities of interest. If informative prior information were available on
the risk-analytic quantities under study, the ambiguous interpretation(s) of these traditional,
regression-type parameterizations makes incorporation of such information more difficult.
This may hinder effective application of the Bayesian approach in this benchmark setting.
2.2 Reparameterizing the Quantal Response Models
For benchmark risk analysis, we argue (Fang and Piegorsch, 2014) that substantive prior
knowledge may be available more often than usually considered, but not in the form of in-
formation on regression-type β-parameters. Instead, a risk assessor, toxicologist, or other
domain expert would typically have prior knowledge about the target parameter, the BMD,
and possibly also about other application-specific values. Our goal is to utilize the do-
main expert’s prior knowledge for making inferences on the BMD. To do so, we follow
Fang and Piegorsch (2014) and reparameterize R(d) in terms of ostensibly meaningful pa-
rameters whose prior distributions are more intuitive to elicit in practice.
For the dose-response models with two parameters in Table 2, we reparameterize in
terms of the target value, BMD (denoted in the sequel as ξ), and the background risk, say,
γ0 = R(0). Thus θ becomes the vector [ξ γ0]
T.
For the models with three unknown parameters in Table 2, we reparameterize with ξ
= BMD, γ0 = R(0), and a parameter γ1 defined as R(dℓ) for some non-zero dose level dℓ.
Unless otherwise specified, we set dℓ to the highest dose, so γ1 = R(dm). Thus, we take
θ = [ξ γ0 γ1]
T. The latter two quantities are technically nuisance parameters as far as the
BMD is concerned, but one or both are nonetheless likely to be associated with non-trivial
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prior information; e.g., historical control data may inform γ0 = R(0) (Wheeler and Bailer,
2012; Shao, 2012).
For instance, consider a highly popular three-parameter model from carcinogenicity as-
sessment, the two-stage version of the multi-stage model (Armitage and Doll, 1954; Nitcheva et al.,
2007). This is model M5 in Table 2:
R(d) = 1− exp{−β0 − β1d− β2d2}, (2.2)
where βj ≥ 0 for all j = 0, 1, 2. It is fairly straightforward to apply our reparameterization
strategy and represent the three β-parameters in terms of θ = [ξ γ0 γ1]
T; we explicate this
in a Supplementary Document. The result is
R(d) = γ0 + (1− γ0)
[
1− exp
{
C5dmd(dm − d) + Γ5ξd(ξ − d)
ξdm(ξ − dm)
}]
(2.3)
where Γ5 = log
(
1−γ1
1−γ0
)
and C5 = − log(1−BMR). Admittedly, this is much less compact than
the common form in (2.2), but it nonetheless gives an expression that can be manipulated
effectively for Bayesian benchmark analysis.
In similar fashion, the remaining models in Table 2 can be reparameterized as follows:
M1: R(d) =
[
1 + exp
{
−logit(γ0)− dξ log
(
1+exp{−logit(γ0)}·BMR
1−BMR
)}]−1
.
M2: R(d) = Φ
(
Φ−1{γ0}+ Φ
−1{BMR[1−γ0]+γ0}−Φ−1(γ0)
ξ d
)
.
M3: R(d) = 1− exp
{
log(1− γ0) + log(1−BMR)ξ d
}
.
M4: R(d) = γ0 + (1− γ0)
(
1− exp
{
log(1−BMR)
ξ2
d2
})
.
M5: See Equation (2.3).
M6: R(d) = γ0 + (1− γ0)
[
1 + exp
{
C6[log dm−log d]+Γ6[log ξ−log d]
log ξ−log dm
}]
,
where Γ6 = log
(
1−γ1
1−γ0
)
and C6 = log
(
BMR
1−BMR
)
.
M7: R(d) = γ0 + (1− γ0)Φ
(
C7[log dm−log d]+Γ7[log d−log ξ]
log dm−log ξ
)
,
where Γ7 = Φ
−1
(
γ1−γ0
1−γ0
)
and C7 = Φ
−1(BMR).
M8: R(d) = γ0 + (1− γ0)
(
1− exp
{
− exp
(
C8[log dm−log d]+Γ8[log d−log ξ]
log dm−log ξ
)})
,
where Γ8 = log
(
− log
(
1−γ1
1−γ0
))
and C8 = log(− log(1− BMR)).
Here again, these reparameterizations present more burdensome notation for R(d). The
explicit incorporation of the target parameter ξ and well-understood quantities such as γ0
and γ1 allows us, however, to formulate a clearer, more application-oriented hierarchical
model, from which to produce inferences on ξ.
5
2.3 Bayesian Benchmark Analysis under Reparameterized Quan-
tal Response Models
Generically, under our reformulation we assign a joint p.d.f. to θ: pi(θ) = pi(ξ, γ0) for the
two-parameter quantal-response models, or pi(θ) = pi(ξ, γ0, γ1) for the three-parameter mod-
els. Mimicking previous Bayesian constructions for benchmark analysis (Shao and Small,
2011; Shao, 2012), we assume the unknown parameters enter into the prior independently,
so that pi(ξ, γ0) = pi(ξ)pi(γ0) or pi(ξ, γ0, γ1) = pi(ξ)pi(γ0)pi(γ1).
For the non-negative, target quantity ξ we employ an inverse gamma prior: ξ ∼ IG(α, β)
with marginal prior density pi(ξ|α, β) = βα
Γ(α)
ξ−(α+1)e−β/ξI(0,∞)(ξ), where Γ(a) is the usual
Gamma function and IA(x) is the indicator function that returns 1 if x ∈ A and 0 otherwise.
For the probability parameter γ0 = R(0) we take γ0 ∼ Beta(ψ, ω) with marginal prior
pi(γ0|ψ, ω) = Γ(ψ+ω)Γ(ψ)Γ(ω)γψ−10 (1 − γ0)ω−1I(0,1)(γ0). Where needed (models M5–M8) we similarly
set γ1 ∼ Beta(κ, λ).
The various hyperparameters—α, β, ψ, ω, κ and λ—require complete specification for
implementation of the model as we propose it. To do so, we first attempt to elicit each
prior by incorporating subject-matter knowledge of the associated quantities from either an
individual domain expert or previous information in the literature (or both). Since the IG
and beta priors each have two parameters, two associated quantities are needed. Based on
interactions with toxicologists and risk assessors, we find that for the target parameter ξ,
specification of the first/lower quartile (Q1) along with the median (Q2) of the IG prior is
most propitious (Fang and Piegorsch, 2014) . Similarly, for the Beta prior on γ0 (and γ1) we
also elicit the two quartiles Q1 and Q2. We then numerically solve the resulting system of
equations for the pertinent hyper-parameters given the two quartiles. Details are provided
in the Supplementary Document.
When elicitation is not possible, we default to objective specifications for the prior den-
sities. We favor a simple approach: for an objective prior on ξ, use the proper prior,
ξ ∼ IG(0.001, 0.001). This IG prior is a popular suggestion in the literature for right-skewed,
positive values (Lambert et al., 2005; Christensen et al., 2011, §1.2), such as the BMD. It is
in effect an approximation of the conventional improper reciprocal prior for positive quan-
tities, i.e., pi(ξ) ∝ 1/ξ (O’Hagan, 1994, §9.17). To ensure computational stability, following
guidance from Fang and Piegorsch (2014), we perform all our hierarchical calculations with
doses scaled so that the maximum administered dose equals 1. For an objective prior on
either γ0 and/or γ1, we choose another conventional, objective prior for proportions, the
univariate Jeffreys prior: Beta
(
1
2
, 1
2
)
.
From these, the posterior p.d.f. for θ under the two-parameter dose-response models is
pi(ξ, γ0|Y ) =
∏n
i=1
(
Ni
Yi
)
R(di)
Yi[1− R(di)]Ni−Yi
m(Y )
βαe−β/ξ
Γ(α)ξα+1
Γ(ψ + ω)
Γ(ψ)Γ(ω)
γψ−10 (1− γ0)ω−1 (2.4)
over ξ > 0 and 0 < γ0 < 1. A similar form emerges when considering the three-parameter
dose-response models.
The denominator of pi(ξ, γ0|Y ) in (2.4) contains the marginal likelihood
m(Y ) =
∫ ∞
0
∫ 1
0
f(Y |ξ, γ0)pi(ξ|α, β)pi(γ0|ψ, ω)dγ0dξ,
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where f(Y |ξ, γ0) is the binomial likelihood. This marginal is intractable under our elicited
prior structure, unfortunately, and to evaluate (2.4) we turn to Monte Carlo posterior ap-
proximations that produce simulated realizations θk, k = 1, . . . , K of the parameter vec-
tor from the posterior distribution. Our choice for the Monte Carlo technique employs an
adaptive Metropolis (AM) strategy, which tunes the variance of the underlying Metropolis
proposal density adaptively when generating ongoing draws of the chain. From our experi-
ence with a variety of such methods, we favor a global AM procedure with componentwise
adaptive scaling described by Andrieu and Thoms (2008). Details are similar to those in
Fang and Piegorsch (2014) and are given in the Supplementary Document.
We monitor convergence of the AM sample to the posterior joint distribution via standard
MC diagnostics. We include a burn-in over the first K0 − 1 draws, where we choose K0 to
be much smaller than K. K0 is determined from a series of diagnostics given by Geweke
(1992). (Again, details can be found in the Supplementary Document.) If the diagnostics
indicate that convergence is not evidenced, we flag the result as an ‘algorithm failure.’ In
Fang and Piegorsch (2014) we found such failures to be rare events; they usually appear
with very shallow dose-response patterns. Our experience also suggests that K = 100, 000
iterations of the AM chain, including burn-in, generally provide stable results. From these,
we use the remaining K∗ = K −K0 + 1 draws to approximate the joint posterior for θ.
For estimating the BMD, one can follow a standard approach and select the Bayes esti-
mator as the posterior mean of the AM sample (Casella and Berger, 2002, §7.2.3). Other for-
mulations are also possible; see Fang and Piegorsch (2014). For the corresponding Bayesian
BMDL, say, ξ100BMR, we find the one-sided, lower, 100(1 − α)% credible limit on ξ, satisfy-
ing P (ξ > ξ100BMR|Y ) = 1 − α. At the traditional level of α = 0.05, we desire the lower
5th percentile of pi(ξ|Y ), and we approximate this using the lower 5th percentile from our
Monte Carlo sample of ξ. If {ξ(k)}K∗k=1 denotes the ordered values from the retained chain,
our Bayesian BMDL takes the form ξ100BMR = ξ(⌊0.05K∗⌋), where ⌊x⌋ is the floor function that
returns the largest integer smaller than x.
3 Bayesian Model Averaging
The selection of parametric forms for R(d) presented in §2.2 illustrates the wide vari-
ety of dose-response functions available to the risk analyst. Many of these operate well at
(higher) doses near the range of the observed quantal outcomes; however, they can produce
wildly different estimates on BMDs at very small levels of risk (Faustman and Bartell, 1997;
Kang et al., 2000). The corresponding issue of model uncertainty has bedevilled benchmark
analysts since its introduction in the mid-1980s. Some users have turned to formal model
selection procedures to derive the BMD (Davis et al., 2012). This is a natural option, al-
though it relies on a reliable selection criterion. In fact, model selection based on the popular
Akaike information criteria (AIC) (Akaike, 1973) has been shown to select incorrect models
for BMD estimation almost as often as it selects correct models (West et al., 2012). As an
alternative to simple model selection methods, and to provide a more model-robust option
for BMD estimation, we consider here a (Bayesian) model averaging approach.
Suppose Q > 1 quantal-response models are under consideration such as the Q = 8
models in Table 2. These form an uncertainty class UQ, with individual model elements
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Mq (q = 1, . . . , Q). Following Hoeting et al. (1999), the model-averaged posterior density for
ξ is defined as a mixture of marginal posterior densities for ξ under each model, f(ξ|Y ,Mq),
with the individual-model posterior probabilities P (Mq|Y ) employed as weights:
f(ξ|Y , UQ) =
Q∑
q=1
f(ξ|Y ,Mq)P (Mq|Y ). (3.1)
The posterior model probabilities in (3.1) are obtained through Bayes’ formula:
P (Mq|Y ) = m(Y |Mq)P (Mq)∑Q
q=1m(Y |Mq)P (Mq)
, (3.2)
where P (Mq) are the prior model probabilities andm(Y |Mq) are the marginal likelihoods for
each qth model. If the risk assessor has no preference for any particular model, a reasonable
default views the Mqs as equally valid, so that P (Mq) = 1/Q ∀q. The posterior model
probabilities are then simply P (Mq|Y ) = m(Y |Mq)∑Q
q=1 m(Y |Mq)
.
Clearly, the challenge with this sort of Bayesian model averaging (BMA) is to estimate
the P (Mq|Y ) values. This requires accurate estimation of the marginal likelihood m(Y |Mq).
Unfortunately, under our reparameterized hierarchy the associated integral is intractable.
To approximate it, we employ the geometric bridge sampler of Meng and Wong (1996); also
see Lopes and West (2004). Bridge sampling is relatively convenient and quite suitable for
estimating marginal likelihoods from an AM sample. (Greater detail is provided in the
Supplementary Document.) As pointed out by Hoeting et al. (1999), under a squared error
loss function the BMA estimate of ξ is then straightforward to calculate. Simply take the
weighted average of the individual-model, posterior sample mean estimates of ξ100BMR across
the uncertainty class:
ξ¯100BMR =
Q∑
q=1
wq ξˆ100BMR;q , (3.3)
where the weights are the posterior model probabilities, wq = P (Mq|Y ). The primary focus
in benchmark analysis is, however, the BMDL. To find a Bayesian BMA-based 95% BMDL
we write P (ξ ≤ ξ
100BMR
|Y , UQ) = 0.05, where ξ has p.d.f. defined by (3.1). From our AM
sample, we approximate this via
P (ξ ≤ ξ
100BMR
|Y , UQ) ≈
Q∑
q=1
wq
1
K∗q
K∗q∑
j=1
I{ξj ≤ ξ
100BMR
|Mq},
where K∗q is the size of the AM sample from model Mq (after burn-in) and I denotes the
indicator function. Thus the estimated BMA BMDL satisfies the equation
Q∑
q=1
wq
1
K∗q
K∗q∑
j=1
I{ξj ≤ ξ
100BMR
|Mq} = 0.05.
The solution is found numerically. (Again, technical details are given in the Supplementary
Document.)
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4 Example: Benchmarking Carcinogenicity of Cumene
To illustrate our hierarchical BMA approach with the Q = 8 reparameterized models in §2.2,
we returned to the cumene carcinogenicity data in Table 1. The BMR was set to the standard
default level of 0.10 (U.S. EPA, 2012), and for the computations all experimental doses were
scaled such that the maximum dose was equal to 1. With input from domain experts, we
based prior elicitation for ξ and γ0 on existing background in the toxicological literature.
(Specifics are given in the Supplemental Document.) This led to the prior distributions
ξ ∼ IG(0.53, 0.13) and γ0 ∼ Beta(1.36, 12.31). For the three-parameter models, we required
an additional prior specification for γ1 = R(dm) at dm = 1 (i.e., d = 500 ppm on the original
scale). Unfortunately, no prior information was available on potential response of the tested
animals at this (or any listed) dose of cumene (U.S. NTP, 2009). Thus we defaulted to use
of an objective prior: γ1 ∼ Beta(12 , 12).
With this prior structure in place, we generated a Monte Carlo AM sample for each of
the eight models. We encountered no algorithm failures, and the eight generated chains
all passed our convergence diagnostic tests. This produced burn-ins of 10, 000 initial itera-
tions for each chain, allowing us to operate with 90, 000 AM draws for each model. Using
the methods described above, this led to model-specific, posterior-mean benchmark concen-
trations (BMCs) as reported in Table 3 (all final BMC values are rescaled to the original
dose metric). The table also lists the corresponding 95% model-specific BMCLs, along with
the posterior model probabilities/weights, wq = P (Mq|Y ), assuming uniform prior model
probabilities for each model. The eight BMC were then used to calculate the BMA BMC
ξ¯10 = 27.4074 ppm by using (3.3). The corresponding 95% BMCL is ξ10 = 15.1927 ppm.
These two values are also reported at the bottom of Table 3.
Table 3: BMC estimates based on posterior means and 95% BMCLs (in ppm) from each repa-
rameterized model in §2.2, along with corresponding Bayesian model averaged (BMA) BMDL, for
cumene carcinogenesis example. The BMR is set to 0.10.
Model BMC10 BMCL10 P (Mq|Y )
M1 43.2752 35.5991 0.00044
M2 44.7192 37.6845 0.00005
M3 18.0881 14.7567 0.22887
M4 76.3691 66.2304 0.00000
M5 21.2154 16.2568 0.01356
M6 31.1642 15.9229 0.36905
M7 30.1092 15.3244 0.34956
M8 24.2385 17.0606 0.03846
BMA 27.4074 15.1927
From the table, we see that the posterior model probabilities vary widely with these data,
suggesting that certain models may provide better-quality estimates than others. The three-
parameter log-logistic and log-probit give the highest weights, both near 35%, followed by the
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two-parameter quantal linear model at 23%. All other models show posterior probabilities
below 5%. The BMA 95% BMCL is 15.1927 ppm, lying within the range of the individual
model BMCLs and closer to the individual lower limits associated with higher-weight models.
The ramifications with these data for the risk analyst are substantial: had a choice of the
poorly-fitting logistic, probit, or quantal-quadratic models been made for analyzing these
data, the consequent BMC and BMCL would have been far too large. By integrating in-
formation across the various models, however, a more-tempered, model-robust estimate is
produced from which further risk analytic calculations on cumene carcinogenicity can be
conducted. Corroborating reports by many who have come before, we find that BMA ad-
justment frees the risk assessor from the selection biases, model inadequacies, and inferential
uncertainties one encounters when committing to only a single parametric model to perform
the benchmark analysis.
5 Performance Evaluations
5.1 Simulation design
To explore the features of our Bayesian model-averaged BMD/BMDLs in further detail,
we conducted a short simulation study. We fixed the BMR at the standard level of BMR =
0.10 (U.S. EPA, 2012) and operated at a credible level of 95%. The doses were set to four
levels: d1 = 0, d2 = 0.25, d3 = 0.5, d4 = 1, corresponding to a standard design in cancer risk
experimentation (Portier, 1994). Equal numbers of subjects, Ni = N , were taken at each
dose group. We considered three different per-dose sample sizes: N = 25, 50, or 1000; the
latter approximates a ‘large-sample’ setting, while the former two are more commonly seen
with toxicological investigations such as that in the cumene carcinogenicity example. As
throughout, all of our calculations were performed within the R programming environment
(R Development Core Team, 2012).
For the true dose-response model R(d), we used each of the eight quantal-response func-
tions in Table 2. We considered two different dose-response patterns, from a larger collection
studied by West et al. (2012). The first pattern (P-I) was a moderately increasing response
with γ0 = R(0) = 0.05, R(
1
2
) = 0.30, and R(1) = 0.50. The second pattern (P-II) was more-
broadly increasing, with γ0 = R(0) = 0.10, R(
1
2
) = 0.50, and R(1) = 0.90. The resulting
parameter configurations for the various models are given in Table 4.
At each of the 8 (models) × 2 (configurations) × 3 (sample sizes) = 48 combinations, we
simulated 2000 pseudo-binomial quantal-response data sets via R’s rbinom function. Then
for each data set, we generated eight AM samples, one from each model Mq. We then
calculated the model-specific 95% BMDL ξ10;q as the lower 5
th percentile of each model’s
AM sample. For simplicity, no prior elicitation was applied in the simulations and so we
employed only objective priors for ξ, γ0 and γ1, i.e., ξ ∼ IG(0.001, 0.001), γ0 ∼ Beta(12 , 12),
and γ1 ∼ Beta(12 , 12), to represent parameter uncertainty.
Assuming uniform prior model probabilities, the posterior model probabilities were calcu-
lated using geometric bridge sampling. We employed these posterior probabilities P (Mq|Y )
as weights and computed the BMA BMDLs according to the methods described in §3.
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Table 4: Models and configurations for simulation study. Model codes are from Table 2
Dose-Response Model
Configuration Parameters M1 M2 M3 M4 M5 M6 M7 M8
P-I
γ0 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
ξ 0.3974 0.3567 0.1642 0.4052 0.1783 0.2083 0.2267 0.1852
γ1 — — — — 0.50 0.50 0.50 0.50
P-II
γ0 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
ξ 0.1700 0.1575 0.0480 0.2190 0.1925 0.2760 0.2794 0.2025
γ1 — — — — 0.90 0.90 0.90 0.90
5.2 Simulation Results
We studied how the BMA BMDL compared to the corresponding generating value of
ξ10 in Table 4. In some sense, we expect 95% of these lower credible limits to lie below ξ10
and using our simulations as a guide, we queried how often this occurred. Figure 1 provides
representative boxplots of the 2000 simulated BMA BMDLs under model M6 (log-logistic)
and configuration P-I at the popular per-dose sample size of N = 50. Mimicking a device
employed by West et al. (2012), the boxplots are asymmetrically modified so that their upper
whiskers stop at the 95th percentile of the 2000 simulated BMA BMDLs. (The lower whiskers
rest at the minimum BMDL. The hinges and median bar are the usual quartiles.) Thus the
‘goal’ for each boxplot is to locate its upper whisker as close to, but not greatly exceeding,
the generating value of ξ10. A horizontal dashed line in the figure marks this ξ10 target.
0
.0
0
.1
0
.2
0
.3
0
.4
M1 M2 M3 M4 M5 M6 M7 M8 BMA
Figure 1: Modified Box plots for 95% individual-model BMDLs and BMA BMDL using simulated
data from model M6, configuration P-I, and sample size N = 50. (See text for details.) BMR is
set to 0.10. Dashed horizontal line indicates target BMD10 under this model configuration.
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The eight modified boxplots in Figure 1 correspond to model-specific 95% BMDLs calcu-
lated under each of the eight models in Table 2. The modified boxplot at far right gives the
result for our 95% BMA BMDL. The graphic illustrates the consequences and ambiguities of
single-model uncertainty when calculating Bayesian BMDLs. Recall that M6 is the generat-
ing model and as anticipated, the M6 boxplot for our single-model Bayesian BMDL displays
acceptable characteristics: its modified upper whisker is slightly below the ξ10 target. It also
exhibits a right skew, however, with median BMDL conservatively lower than any of the
others in the figure.
The figure also illustrates the perplexing operating characteristics of single-model BMDLs
under model misspecification: when M1, M2, and (particulary) M4 are employed individually
in the hierarchy, their BMDLs badly overestimate the ξ10 target. BMDLs using models M5
and M8 are somewhat more-stable; BMDLs using model M3 show the least variation while
locating conservatively below the ξ10 target. Analogous instances of stable/unstable single-
model BMDLs occurred for all the model-configuration combinations we studied, but with
no clear pattern as to which models operated well or poorly when misspecified. [Complete
results from all 48 configurations are available in Fang (2014).]
On balance, however, the modified boxplot for the BMA BMDL at the far right of Figure
1 displays reasonable operating characteristics. As desired, its modified upper whisker lies
just below the target ξ10, and it locates a broader collection of ξ10 limits closer to that
target, without exceeding it, than even the correct-model M6 boxplot. (Admittedly, the M3
and perhaps M5 boxplots display even better performance here; however, these models did
not exhibit consistently enhanced performance across all the configurations we studied.)
We find that unequivocal commitment to a specific dose-response model when there is
any possibility of it being misspecified can lead, as often as not, to substantial overestima-
tion of the benchmark point(s). Misspecifying the model sometimes produces acceptable
lower limits, but we were not able to identify any predictable pattern of such among our
simulation results. [This corroborates similar indications by West et al. (2012) for single-
model, frequentist BMDL calculations.] By contrast, the Bayesian BMA BMDL provides a
reasonable compromise.
Figure 2 extends this analysis to the large-sample setting, displaying a similar graphic
when the per-dose sample size is N = 1000. Here, we highlight results for model M3 under
configuration P-II. As we might expect with such a large N , no single-model fit exhibits
acceptable performance, save that of the correct model (M3) and possibly models M5 and
M8. (Notice that model M3 is a special case of both M5, with β2 = 0, and M8, with β1 = 1,
in Table 2. As in Figure 1, these three models sometimes perform similarly, although we also
found cases where their operating characteristics diverged.) Moving to the BMA BMDL,
however, overcomes these negative characteristics: the BMA BMDL boxplot at far right is
almost identical to that for the correct-model M3 boxplot. Here again, the BMA BMDL
provides valuable robustness in the presence of model uncertainty/misspecification.
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Figure 2: Modified Box plots for 95% individual-model BMDLs and BMA BMDL using simulated
data from model M3, configuration P-II, and sample size N = 1000. (See text for details.) BMR is
set to 0.10. Dashed horizontal line indicates target BMD10 under this model configuration.
6 Discussion
Herein, we consider a strategy for model averaging within a hierarchical Bayesian frame-
work when estimating benchmark doses (BMDs) in quantitative risk analysis. Placing em-
phasis on biomedical risk assessment, our approach estimates the BMD from a series of
reparameterized quantal-response models with meaningful parameters (including the BMD
itself) and accounts for potential model uncertainty via Bayesian model averaging (BMA).
A mixture posterior density is constructed for the BMD, and is used to find the BMA point
estimate (Hoeting et al., 1999). The BMA lower credible limit (BMDL) is estimated as the
lower αth percentile of the mixture posterior. Risk analysts can apply this method to avoid
concerns of model uncertainty in multimodel problems, and to construct inferences on the
BMD by incorporating prior knowledge for the uncertainty associated with pertinent model
parameters.
Of course, some caveats and qualifications are in order. Our reparameterized dose-
response models are highly complex and for the three-parameter forms they can become
rather unwieldy. For instance, Fang (2014) notes that reparameterizations using γ1 can
produce unstable estimates when the highest dose level in the design is very close to the
estimated BMD. In a series of additional simulations (results not shown) we constructed
such a parameter setting where the generating value of ξ10 was slightly larger than dm. We
found that use of the three-parameter models often resulted in algorithm failures when an
individual-model ξˆ drew near to dm. Thus in cases where the BMD is felt to be near the
highest dose—as determined, e.g., from elicited prior information—we recommend revising
the reparameterization for γ1 to define it as the response at some lower dose, say, R(d2).
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This can ameliorate the instabilities that occur when ξˆ is near dm.
It is also of interest to investigate how our approach operates under different design config-
urations. We focused on a geometric, four-dose design, arguably the quintessential standard
in cancer and laboratory-animal toxicity testing. We may gain greater information about the
pattern of dose response and therefore about the BMD, however, if we increase the number
of doses and/or change the dose spacings. Experimental design for dose-response studies
with focus on the BMD is an emerging area in the statistical literature (Muri et al., 2009;
O¨berg, 2010; Sand et al., 2008; Shao and Small, 2012) and how to optimally design/allocate
experimental resources for BMD estimation and inferences under a Bayesian paradigm is an
emerging question.
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This supplementary document provides supporting material for Bayesian Model-Averaged Bench-
mark Dose Analysis Via Reparameterized Quantal-Response Models by Qijun Fang et. al., (the
‘main document’). The various sections below address a variety of supplemental/supporting top-
ics, and are not intended to flow naturally between each other. They are, however, presented in
roughly the same order in which their counterpart topics appeared in the main document. As there,
we denote the Benchmark Dose (BMD) target parameter as ξ at a Benchmark Response (BMR)
between 0 and 1, the background response probability nuisance parameter as γ0 = R(0) and the
response at the highest dose, dm, as γ1 = R(dm).
1 Example of reparameterizing Model M5, the two-stage model
Here we study the two-stage model (M5) to illustrate the reparameterization process, originally
proposed in Fang and Piegorsch (2014). The risk function is
R(d) = 1− exp(−β0 − β1d− β2d
2), (S.1)
where βj ≥ 0 (j = 0, 1, 2). With this, γ0 = R(0) = 1 − exp(−β0), hence exp(−β0) = 1 − γ0.
Substitute exp(−β0) = 1− γ0 into the risk function to find
R(d) = γ0 + (1− γ0)[1− exp{−β1d− β2d
2}]. (S.2)
Next, we reexpress β1 and β2 in terms of ξ, γ0 and γ1. Begin with γ1, expressed in terms of γ0, β1
and β2. From the definition of γ1, we know
γ1 = γ0 + (1− γ0)[1 − exp{−β1dm − β2d
2
m}],
where dm denotes themth (highest) dose level. Let Γ5 = log
(
1−γ1
1−γ0
)
. After some algebra, we obtain
β2d
2
m + β1dm + Γ5 = 0. (S.3)
Now, Piegorsch and Bailer (2005, Ex. 4.12) show that the BMD for the two-stage model can be
found to be
ξ =
−β1 +
√
β21 − 4β2 ln(1− BMR)
2β2
. (S.4)
For simplicity, denote C5 = − ln(1− BMR). Then from Equation (S.4), we have
β2ξ
2 + β1ξ −C5 = 0. (S.5)
If we solve Equation (S.3) for β1, we find β1 = (−Γ5 − β2d
2
m)/dm. Substitute the result into (S.5)
to achieve
β2 =
Γ5ξ + C5dm
ξdm(ξ − dm)
. (S.6)
1
Similarly, if we solve Equation (S.3) for β2, then β2 = (−Γ5−β1dm)/d
2
m. Substitute the result into
(S.5) to achieve
β1 =
C5d
2
m + Γ5ξ
2
ξdm(dm − ξ)
. (S.7)
So far, we have rewritten β1 and β2 in terms of Γ5 (or γ0 and γ1) and ξ. The reparameterized
risk function is obtained by substituting these expressions into Equation (S.2). This produces
R(d) = γ0 + (1− γ0)
[
1− exp
{
C5dmd(dm − d) + Γ5ξd(ξ − d)
ξdm(ξ − dm)
}]
, (S.8)
where Γ5 = log
(
1−γ1
1−γ0
)
and C5 = − log(1 − BMR). Similar sorts of operations may be applied to
reparameterize any of the quantal-response models in main document Table 2 (Fang, 2014).
2 Finding prior parameters from elicited quantiles
We give here technical aspects on derivation of the prior parameters α, β, ψ, ω, κ and λ for
the prior densities ξ ∼ IG(α, β), γ0 ∼ Beta(ψ, ω) and γ1 ∼ Beta(κ, λ) used in the main document’s
hierarchical model. The elicited lower quartiles and medians Q1ξ, Q2ξ for ξ, Q1γ0 , Q2γ0 for γ0,
and Q1γ1 , Q2γ1 for γ1, respectively, are assumed given from domain-expert input and/or previous
literature/data.
Start with the elicitation for ξ: by definition, Q1ξ and Q2ξ satisfy∫ Qjξ
0
βα
Γ(α)
ξ(−α−1) exp
{
−
β
ξ
}
dξ =
j
4
,
(j = 1, 2), where the integrand is the IG p.d.f. This establishes a system of non-linear equations
for α and β. Unfortunately, no closed-form solution exists for the system, and so we turn to
numerical methods. We employ a gradient method discussed by Barzilai and Borwein (1988) and
implemented in the R statistical environment (R Development Core Team, 2012) via the BB package
(Varadhan and Gilbert, 2009). This method employs iterative updating until half the L2 norm of
the system at the proposed solution is smaller than 10−10. The iterative solution represents the
‘elicited’ values for α and β.
For γ0, the elicited quartiles Q1γ0 and Q2γ0 satisfy∫ Qjγ0
0
Γ(ψ + ω)
Γ(ψ)Γ(ω)
γψ−10 (1− γ0)
ω−1dγ0 =
j
4
,
(j = 1, 2), now applying the p.d.f. for the Beta prior. Here again, the resulting system of non-linear
equations possesses no closed-form solution, so we appeal to the BB package in R to produce the
elicited values for φ and ω. In similar fashion, and where necessary, given elicited quartiles Q1γ1
and Q2γ1 for γ1, we solve for κ and λ in γ1 ∼ Beta(κ, λ).
The resulting iterative solutions to these systems of equations produce values for the prior
parameters α, β, ψ, ω, κ and λ which are then employed in our hierarchical model for the BMD.
3 Screen to check for ’data failures’
As described in Fang and Piegorsch (2014), some patterns of dose response can be problematic
for benchmark dose estimation. Our experience shows that a shallow dose response can create
2
unstable frequentist ξˆ100BMR estimates, and very shallow responses may cause the iterative model
fit to fail entirely. Indeed, the EPA’s BMDS software program will not estimate a BMD for a flat
or negatively trending dose response (Wheeler and Bailer, 2009). For these reasons, we mark flat
or decreasing-trend data as ‘data failures’ and not perform estimation for them.
To check the acceptability of the data before employing the algorithm, our simple screen is
performed as follows: Over increasing doses 0 = d1 < . . . < di < . . . < dm (i = 1, . . . m), we first
calculate the empirical extra risks:
R˜E(di) =
Yi
Ni
− Y1N1
1− Y1N1
.
We then connect each point (di, R˜E(di)) to the origin point and find the largest slope, Smax, among
all m− 1 rays. If Smax ≤ 0, no increasing trend is evidenced and we mark this as a ‘data failure.’
Notice that we do not perform a formal trend test to detect a decreasing trend (Wheeler and Bailer,
2009), but we do require that at least one estimated risk at some di (i > 1) is higher than the
estimated background risk.
4 The adaptive Metropolis (AM) algorithm
For data passing the simple ‘data failure’ screen in §3, we perform posterior simulation via
a global AM procedure with componentwise adaptive scaling described by Andrieu and Thoms
(2008). Their ‘AM6’ algorithm uses all previous iterations in the chain to update the variance-
covariance matrix of the current bivariate proposal density. The operation is global in the sense
that all the parameters (here, ξ and γ0 for our two-parameter models and ξ, γ0 and γ1 for our
three-parameter models) are updated simultaneously at each bivariate or trivariate draw. It is
componentwise in the sense that the updating step sizes for ξ and γ0 (or ξ, γ0 and γ1 for the three-
parameter models) are controlled by separate adaptive scaling parameters. See Andrieu and Thoms
(2008) for further details.
Denote θ as the parameter vector ([ξ γ0]
T
for the two-parameter case or [ξ γ0 γ1]
T
for the three-
parameter case). Let vk,1, . . . , vk,U be adaptive scaling parameters and set Vk = diag (vk,1, . . . , vk,U )
at the kth draw in the Monte Carlo chain (k = 1, . . . ,K). (U denotes the dimension for the
parameter vector; U = 2 for our two-parameter models and U = 3 for the three-parameter models.)
Take α as the acceptance probability in the normal random-walk Metropolis sampler, i.e.,
α(θk,θk + Zk+1) = min
{
1,
pi(θk|Y )
pi(θk + Zk+1|Y )
}
.
For notation in what follows, set eU as a length-U canonical vector with uth element equal to 1 and
all others 0. Denote sk as a step-size parameter that makes {sk}
∞
k=1 a decaying sequence; for exam-
ple, the deterministic specification sk = 1/k
p, with p > 0 is employed here. [Andrieu and Thoms
(2008) recommend setting p > 1/2, while Vihola (2012) suggests p = 2/3. Here, Vihola’s suggestion
is followed and sk = k
−2/3 is used.] A brief description of the AM algorithm follows.
• Find starting values for ξ, γ0, and (where needed) γ1 in the chain as follows: take the starting
point for γ0 by shrinking
Y1
N1
away from 0 or 1 via Y1+0.25N1+0.5 . Similarly, take the starting point for
γ1 as
Yj+0.25
Nj+0.5
, where the index j indicates the jth data observation at which Smax is attained
(see the ‘simple screen’ procedure described in §3). For the two-parameter models, the starting
point for ξ is taken as BMR/Smax. This is obtained by first treating RE(d) = Smaxd as the
approximate extra risk function and then solving for d in the equation BMR = Smaxd. For
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the three-parameter models, the starting point for ξ is taken as BMR/
(
γ10−γ00
1−γ00
)
where γ00
and γ10 are the starting values for γ0 and γ1, respectively. These starting points collectively
become the starting vector for the chain. Denote this as θ1 in the algorithm and let µ1 = θ1.
• Following Andrieu and Thoms (2008), let Σ1 = I where I is the U ×U identity matrix. Next,
set v1,1 = . . . = v1,U =
2.382
U as the initial scaling parameters. Let V1 = diag (v1,1, . . . , v1,U ),
so that V
1/2
1 IΣ
1/2
1 is the initial variance-covariance matrix for use in the joint proposal dis-
tribution.
• Repeat for k = 2, . . . ,K:
1. Given µk−1, Σk−1 and vk−1,1, . . . , vk−1,U , sample from a multivariate normal proposal
distribution: Zk ∼ N(0, V
1/2
k−1Σk−1V
1/2
k−1) and set θk = θk−1 + Zk with probability
α(θk−1,θk−1 + Zk). Otherwise, set θk = θk−1.
2. Update as follows for u = 1, . . . , U :
log(vk,u) = log(vk−1,u) + sk[α(θk−1,θk−1 + Zk(u)eu)− α¯∗∗],
where α¯∗∗ is the acceptance rate of the candidate points generated at each iteration.
Andrieu and Thoms (2008) suggest that α¯∗∗ = 0.44 provides good performance; we
followed their suggestion here.
3. Update as follows for µk and Σk:
µk = µk−1 + sk(θk − µk−1),
Σk = Σk−1 + sk[(θk − µk−1)(θk − µk−1)
T − Σk−1]
5 Monte Carlo ‘burn-in’ diagnostics
To account for potential instability in the early portions of the length-K, bivariate, AM chain
from §4, we include a ‘burn-in’ for the Monte Carlo sample (Gelman et al., 2004, §11.6). We
couple this with the larger question of how to assess the chain’s convergence. Many approaches
exist for diagnosing MCMC convergence (Cowles and Carlin, 1996), and indeed, the issue is a
topic of ongoing debate (Robert and Casella, 2004, §12.2). We mimic a method due to Geweke
(1992), where early portions of the chain are sub-sampled and compared against latter portions to
determine where the larger sample ofK draws begins to exhibit stable performance. To approximate
independence between the two sub-samples, we bifurcate the chain by a gap of no less than K5
consecutive draws.
For summary diagnostics, we calculate the difference in arithmetic means between the two bi-
furcated sub-samples, and divide each difference by its standard error to produce a Z-statistic.
The approximate standard error is taken as the square root of the sum of the variances of each
mean. This is done separately for the ξk, γ0k, and γ1k components. To adjust for possible autocor-
relation within each sub-sample, the individual variances are based on estimated spectral densities
at frequency zero. Two parametric methods of estimating these spectral densities are considered
here. The first method is discussed by Heidelberger and Welch (1981), which consists of fitting a
generalized linear model to the periodogram of the batched time series. We implement this using R,
via the coda package’s spectrum0 function. The second method begins by fitting the periodogram
with an autogressive model, and then use the spectral density of the fitted AR model to approxi-
mate the spectral density at frequency zero. We again implement this method using R, now with
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the coda package’s spectrum0.ar function. These two methods produced similar estimates of the
spectral density at zero. The Heidelberger and Welch method is fast and is the default method in
the coda package, hence we also default to it first. The fit may fail due to high autocorrelation of
the chain, however, and when this happens we then switch to the AR method for estimating the
spectral density at zero.
To monitor if the pattern of association between any two parameters within the larger chain also
exhibits reasonable stability, we include comparison of up to three pairs of covariances between two
sub-samples (for the two-parameter models, only the covariance between ξ and γ0 is considered).
As a diagnostic measure we use the sample covariances from each sub-sample, which are
Ĉov(ξ, γ0) =
1
L
L∑
k=1
(ξk − ξ¯)(γ0k − γ¯0),
Ĉov(ξ, γ1) =
1
L
L∑
k=1
(ξk − ξ¯)(γ1k − γ¯1),
Ĉov(γ0, γ1) =
1
L
L∑
k=1
(γ0k − γ¯0)(γ1k − γ¯1),
where ξ¯, γ¯0 and γ¯1 are the pertinent arithmetic means within a bifurcated sub-sample of length
L (see below). To find the approximate variance of each estimated covariance we calculate the
quantities
τk(ξ, γ0) = (ξk − ξ¯)(γ0k − γ¯0),
τk(ξ, γ1) = (ξk − ξ¯)(γ0k − γ¯1),
τk(γ0, γ1) = (γ0k − γ¯0)(γ1k − γ¯1),
across all values of the index k in the given sub-sample and then estimate the variance of τk(ξ, γ0),
τk(γ0, γ1) and τk(γ0, γ1) based on their estimated spectral densities at frequency zero.
Each such comparison is conducted over three individual, separated bifurcations of the full
K-length sample: (i) the first 10% of the chain (L = K/10) vs. the final 50% (L = K/2), (ii)
the first 20% of the chain (L = K/5) vs. the final 50%, and (iii) the first 30% of the chain
(L = 0.3K) vs. the final 50%. We consider an individual diagnostic comparison as a ‘pass’ if the
corresponding Z-statistic is less than 1.96 in absolute value. For the two-parameter models, to ‘pass’
the full diagnostic at each bifurcation, all three measures—mean of ξ, mean of γ0, and covariance
of {ξ,γ0}—must individually pass; for the three-parameter models, in addition, the mean of γ1, and
the covariances of {ξ, γ1} and {γ0, γ1} must also pass. The comparisons are performed in sequential
order: if the 10%-vs.-50% diagnostic fails, then the 20%-vs.-50% diagnostic is conducted. If this
fails, we move to the 30%-vs.-50% diagnostic. When a diagnostic passes, we view the indicated
early portion of the chain as a reasonable burn-in. For notation, we let K0 < K be the resulting
index that begins the retained portion of the chain. Thus, e.g., if the 10%-vs.-50% diagnostic fails
but then the 20%-vs.-50% diagnostic passes, we take the first 20% of the chain as burn-in and use
the remaining 80% of the chain as our Monte Carlo sample from pi(ξ, γ0|Y ) or pi(ξ, γ0, γ1|Y ). If
K =100,000, as used throughout, this gives K0 =20,001.
If none of the three sequential diagnostics pass, we re-set the random-number generator’s seed
and reassess a new set of K Monte Carlo draws. If after five such re-starts the diagnostic continues
to fail, we report an algorithm failure, and terminate the analysis with the given data set.
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6 Bridge sampling for estimating marginal distributions
As a necessary step to perform Bayesian model averaging, we must calculate an approximation
to marginal likelihoods of the form (with the two-parameter models)
m(Y ) =
∫ ∞
0
∫ 1
0
f(Y |ξ, γ0)pi(ξ|α, β)pi(γ0|ψ, ω)dγ0dξ
for elicited or objective priors pi(ξ|α, β) and/or pi(γ0|ψ, ω). To do so, we constructed a geomet-
ric estimator from our AM sample, appealing to the ‘bridge sampling’ method recommended by
Meng and Wong (1996) and Lopes and West (2004). To approximate the marginal likelihood, an
approximation g(·) to the joint posterior density of (ξ, γ0) is first chosen. For simplicity, we took
g(ξ, γ0) as the bivariate normal density function with mean set to the empirical mean vector and
variance set to the empirical variance-covariance matrix of ξ and γ0, estimated from the AM sam-
ple. Next, a set of K∗ = K − K0 bivariate vectors
{
[ξ∗j γ
∗
0j ]
T
}K∗
j=1
are drawn from g(ξ, γ0). The
marginal p.d.f. is then approximated by substituting the (retained) AM sample, {ξk, γ0k}
K
k=K0
, and
the generated sample from g(ξ, γ0),
{
[ξ∗j γ
∗
0j ]
T
}K∗
j=1
, into the ratio
m̂(Y ) =
1
K∗
∑K∗
j=1
{
pi
(
ξ∗j |α, β
)
pi
(
γ∗0j |ψ, ω
)
f
(
Y |ξ∗j , γ
∗
0j
)
/g
(
ξ∗j , γ
∗
0j
)}1/2
1
K∗
∑K
k=K0
{g (ξk, γ0k) / [pi (ξk|α, β) pi (γ0k|ψ, ω) f (Y |ξk, γ0k)]}
1/2
,
where f(·) denotes the binomial likelihood function and pi(·) denotes the pertinent prior density.
The above expression gives the approximated marginal likelihood for our two-parameter models.
Marginal likelihoods for our three-parameter models are approximated in the same fashion by
including the pi(γ1|κ, λ) prior and using a trivariate approximating normal density g(ξ, γ0, γ1).
7 BMA BMDL calculation
In the main document, we claimed that
P (ξ ≤ ξ
100BMR
|Y , UQ) ≈
Q∑
q=1
wq
1
K∗q
K∗q∑
j=1
I{ξj ≤ ξ
100BMR
|Mq}.
Here we give a simple proof.
Proof. Equation (3.1) in the main document defines the model-averaged posterior density for
the BMD, f(ξ|Y , UQ), as a mixture of marginal posterior densities for ξ under each qth model,
f(ξ|Y ,Mq) using each model’s posterior probability P (Mq|Y ) as the corresponding weight, wq.
Denote F (ξ|Y , UQ) as the model-averaged posterior distribution function for the BMD and
F (ξ|Y ,Mq) as the marginal posterior distribution function for ξ under each model. By integrating
both sides of Equation (3.1), we have
F (ξ|Y , UQ) =
Q∑
q=1
wqF (ξ|Y ,Mq).
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Now, substitute ξ100BMR into the above equation to find
P (ξ ≤ ξ
100BMR
|Y , UQ) = F (ξ
100BMR
|Y , UQ)
=
Q∑
q=1
wqF (ξ
100BMR
|Y ,Mq)
=
Q∑
q=1
wqP (ξ ≤ ξ
100BMR
|Y ,Mq).
Clearly then, the probability, P (ξ ≤ ξ
100BMR
|Y ,Mq) can be approximated by the sample proportion
1
K∗q
∑K∗q
j=1 I{ξj ≤ ξ100BMR|Mq}, where K
∗
q is the size of the AM sample underMq (excluding burn-in)
and I denotes the indication function.
The BMA BMDL is then calculated by finding the root of equation
1
K∗q
K∗q∑
j=1
I{ξj ≤ ξ
100BMR
|Mq} = 0.05.
To solve this equation numerically, we use the R uniroot function. This employs iterative updating
until either an exact root is found or the change in root for one step of the algorithm is less than
2−13.
8 Prior elicitation with the cumene data
To elicit the prior parameters for the cumene data in the main document, we applied input
from domain experts and based the prior elicitation on existing background from the toxicological
literature. We began with the BMD target parameter, ξ: an oral No Observed Adverse Effect
Level (NOAEL) for long-term cumene exposure in rodents was given by the EPA IRIS website
(http://www.epa.gov/iris/subst/0306.htm) as 110 mg/kg-day. Guidance for converting the
oral mg/kg-day metric to inhalation ppm (as used in the original data Table from the main doc-
ument) was available via conversion data given by the California OEHHA (2004): for rodents, 1
mg/kg-day works out to roughly 2.25 ppm. Arguing that a NOAEL is loosely equivalent to a
BMD—although, see (Kodell, 2005) for an in-depth discussion—the median prior estimate was
Q2ξ = 110 mg/kg-day = 247.5 ppm ≈ 250 ppm. For the first quartile, the EPA IRIS site gave a
cumene inhalation NOAEL for rodents as 435 mg/cu.m, based on a shorter, 13-week study. The
shorter exposure period was suited to provide only a conservative estimate on the BMD’s central
tendency; we translated this to use of the 435 mg/cu.m 13-week NOAEL as a prior estimate of
the first quartile. For conversion to inhalation ppm, the EPA indicated that roughly 1 mg/cu.m
= 0.204 ppm, so we took Q1ξ = 435 mg/cu.m = 88.75 ppm ≈ 90 ppm. We then divided the ppm
dose by 500 ppm to standardize the ξ-scale to 0 ≤ ξ ≤ 1. This produced prior first quartile and
median estimates for pi(ξ|α, β) as 0.18 and 0.5, respectively.
For γ0, historical control data on alveolar/bronchiolar tumors in Female B6C3F1 mice were
given by U.S. NTP (2009, Table D3a). These provide direct prior information on the background
risk. The historical data gave a median background response of Q2γ0 = 0.08 and a lower quartile
of Q1γ0 = 0.04.
As noted in the main document, no elicitation for γ1 was available. We found no indication of
carcinogenic effects of cumene evidenced in laboratory mice prior to the NTP’s toxicology study
(U.S. NTP, 2009). As a result, we defaulted to the objective prior γ1 ∼ Beta
(
1
2 ,
1
2
)
.
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These quartile-based elicitations were then used to construct the prior densities ξ ∼ IG(α, β)
and γ0 ∼ Beta(ψ, ω) as described in §1, above.
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